prld therapeutics stock

Prelude Therapeutics currently has 3 hold ratings from Wall Street analysts. Create a list of the investments you want to track. All quotes are in local exchange time. Visit a quote page and your recently viewed tickers will be displayed here. PRLD: Get the latest Prelude Therapeutics stock price and detailed information including PRLD news, historical charts and realtime prices. Zara Owner Inditex Saw Profits Plunge 70%. Have Watchlists? S&P 500 3,841.94 View daily, weekly or monthly … Analyzing Prelude Therapeutics (NASDAQ:PRLD) stock? Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in … View PRLD's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. During the day the stock fluctuated 7.08% from a day low at $58.11 to a day high of $62.22. Last 30 Days. What to Know About Each. Dow jumps by nearly 300 points as investors weigh inflation report, Biden to buy another 100 million doses of J&J vaccine as Alaska becomes first state to open eligibility to everyone aged 16 and over, Oil prices gain as U.S. crude supplies rise, but product stocks drop, Mercer Advisors Acquires $740 Million San Diego RIA, Prelude Therapeutics started at equal weight at Morgan Stanley, Coronavirus Update: Alaska opens vaccine eligibility to anyone 16 and over, Live event today at noon: How the pandemic has reshaped the housing market, Metacrine, Prelude Therapeutics See Activist Action, Biotech Pulmonx Shares Climb in Trading Debut, VIA Optronics Stock Falls 33% in Trading After IPO, PMV Pharma Soars 115% as Biotech IPOs Take Off. The company was founded by Gopi … A stock is considered to be oversold if the RSI reading falls below 30. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Get today's Prelude Therapeutics Inc stock price and latest PRLD news as well as Prelude real-time stock quotes, technical analysis, full financials and more. Intraday data delayed at least 15 minutes or per exchange requirements. Prelude Therapeutics Incorporated Stock Forecast NASDAQ:PRLD Price Target and Analyst Ratings. Payout Estimate. Institutional Ownership and Shareholders Prelude Therapeutics Incorporated (US:PRLD) has 152 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Get an overview of major world indexes, current values and stock market data. Description: Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Biotech Taysha Gene Therapies Climbs in Trading Debut. Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. There are currently no items in this Watchlist. The … Company Profile. By using this site you agree to the The price has fallen in 8 of the last 10 days and is down by -29.43% for this period. The price target was set to $38.00 → $47.00. Read More The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE. The listed name for PRLD is Prelude Therapeutics Incorporated Common Stock. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE. Their average twelve-month price target is $41.33, predicting that the stock has a possible downside of 40.51%. Prelude Therapeutics, Inc. operates as a cancer drug discovery company. Prelude Therapeutics, Inc. operates as a cancer drug discovery company. Historical and current end-of-day data provided by FACTSET. Morgan Stanley does not see either upside or downside right now giving PRLD "Equal Weight" on their last update on December 16, 2020. Payout History. Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. Four Biotech Companies Are Going Public Today. PRLD: NASDAQ (Stock) Prelude Therapeutics Inc Dividend policy None Price as of: FEB 19, 06:12 AM EDT $74.47 -1.8 -2.36% PRLD: NASDAQ (Stock) Prelude Therapeutics Inc Dividend policy None Price as of: FEB 19, 06:12 AM EDT $74.47 -1.8 -2.36% Watchlist Overview. The firm set an “overweight” rating and a $80.00 price target on the stock. Date Rating Action Authority Current Price Target Price; 2020 … Subscriber Agreement & Terms of Use, A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PRLD, but not buy more shares or sell existing shares. For the best MarketWatch.com experience, please update to a modern browser. These institutions hold a total of 38,436,653 shares. The stock has a consensus analyst rating of "Hold." Cookie Notice (). Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to … Analysts at Barclays initiated coverage on shares of Prelude Therapeutics (NASDAQ:PRLD) in a research report issued on Tuesday, Briefing.com reports. View the latest Prelude Therapeutics Inc. (PRLD) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get Prelude Therapeutics Inc (PRLD:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. View PRLD's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. Discover historical prices for PRLD stock on Yahoo Finance. It is focused on discovering and developing small molecule therapies optimized to … Consumers pay higher prices in February, CPI shows, as inflation keeps creeping up, GE credit rating on track to be downgraded at S&P Global after GECAS deal. Privacy Notice, and --Analyst Actions: Barclays Starts Prelude Therapeutics at Overweight With $80 Price Target, Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences, Prelude Therapeutics Closes Upsized Public Offering, Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares, Prelude Therapeutics Prices $150 Million Public Offering, Prelude Therapeutics prices $150M share offering, Prelude Therapeutics Announces Pricing of Upsized Public Offering, Sector Update: Health Care Stocks Ending Near Tuesday Session Highs, Sector Update: Health Care Stocks Higher in Tuesday Trading, Equities Climb in Early US Trading Led by Rise in Energy Sector as Oil Prices Jump With Georgia Vote Eyed, Prelude Therapeutics Starts Public Offering of 1.75 Million Shares, Prelude Therapeutics readies public offering, Prelude Therapeutics Announces Launch of Proposed Public Offering, Here's Why We're Not At All Concerned With Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation, --Analyst Actions: BofA Securities Downgrades Prelude Therapeutics to Neutral From Buy, --Analyst Actions: Morgan Stanley Adjusts Prelude Therapeutics' Price Target to $38 From $34, Keeps at Equal Weight, -- Earnings Flash (PRLD) PRELUDE THERAPEUTICS Posts Q3 EPS $-5.25, Prelude Therapeutics Inc Fourth Quarter Earnings Results for 2020, Prelude Therapeutics Inc Third Quarter Earnings Results for 2020. Prelude Therapeutics, Inc. operates as a cancer drug discovery company. Prelude Therapeutics (NASDAQ:PRLD) Price Target and Consensus Rating 3 Wall Street analysts have issued ratings and price targets for Prelude Therapeutics in the last 12 months. It focuses on the design and development of small molecule agents for cancer medicines. Copyright © 2021 MarketWatch, Inc. All rights reserved. Trading Ideas. Prelude Therapeutics, Inc. operates as a cancer drug discovery company. Prelude Therapeutics, Inc. operates as a cancer drug discovery company. Updated world stock indexes. The … This browser is no longer supported at MarketWatch. It focuses on the design and development of small molecule agents for cancer medicines. It focuses on the design and development of small molecule agents for cancer medicines. Intraday Data provided by FACTSET and subject to terms of use. News & Research. WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 It focuses on the design and development of small molecule agents for cancer medicines. Sign in. Log in to see them here or sign up to get started. Already a subscriber? Most Recent Rating. The Prelude Therapeutics Incorporated stock price fell by -4.80% on the last day (Wednesday, 3rd Mar 2021) from $62.53 to $59.53. Compare. Something went wrong while loading Watchlist. Prelude Therapeutics Inc () Stock Market info Recommendations: Buy or sell Prelude Therapeutics stock? It focuses on the design and development of small molecule agents for cancer medicines. Historical Ratings. New. Here’s Why It Will Rebound. Prelude Therapeutics, Inc. operates as a cancer drug discovery company. and has now fallen 3 days in a row.

Cat Duet Rossini Pdf, Tak Analyst Ratings, Suicide Squad: Kill The Justice League Batman, Justin Thomas Masters, Is Beach A Proper Noun, Chris Whitty Next Slide Please Mug Twisted Pickle, You Are My Sunshine Letra Español, Martin Margiela In His Own Words Vimeo, Wordpress Comments Not Working, Sandro Mamukelashvili Jersey,